The 36-month beta value for ADAP is also noteworthy at 2.39. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ADAP is 226.49M, and at present, short sellers hold a 2.43% of that float. The average trading volume of ADAP on January 15, 2025 was 2.18M shares.
ADAP) stock’s latest price update
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) has experienced a decline in its stock price by -2.82 compared to its previous closing price of 0.59. However, the company has seen a fall of -12.39% in its stock price over the last five trading days. newsfilecorp.com reported 2025-01-13 that The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – January 13, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.
ADAP’s Market Performance
Adaptimmune Therapeutics Plc ADR (ADAP) has seen a -12.39% fall in stock performance for the week, with a -9.22% decline in the past month and a -34.79% plunge in the past quarter. The volatility ratio for the week is 10.59%, and the volatility levels for the past 30 days are at 8.23% for ADAP. The simple moving average for the past 20 days is -4.41% for ADAP’s stock, with a -40.89% simple moving average for the past 200 days.
Analysts’ Opinion of ADAP
Many brokerage firms have already submitted their reports for ADAP stocks, with H.C. Wainwright repeating the rating for ADAP by listing it as a “Buy.” The predicted price for ADAP in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on July 30, 2024 of the previous year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see ADAP reach a price target of $3.15. The rating they have provided for ADAP stocks is “Sector Outperform” according to the report published on May 30th, 2024.
Bryan Garnier gave a rating of “Buy” to ADAP, setting the target price at $3.60 in the report published on March 24th of the previous year.
ADAP Trading at -13.21% from the 50-Day Moving Average
After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.04% of loss for the given period.
Volatility was left at 8.23%, however, over the last 30 days, the volatility rate increased by 10.59%, as shares sank -1.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.32% lower at present.
During the last 5 trading sessions, ADAP fell by -12.75%, which changed the moving average for the period of 200-days by -63.87% in comparison to the 20-day moving average, which settled at $0.5996. In addition, Adaptimmune Therapeutics Plc ADR saw 6.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADAP starting from Piccina Cintia, who sale 24,531 shares at the price of $0.93 back on Jun 18 ’24. After this action, Piccina Cintia now owns 38,293 shares of Adaptimmune Therapeutics Plc ADR, valued at $22,814 using the latest closing price.
Rawcliffe Adrian, the Chief Executive Officer of Adaptimmune Therapeutics Plc ADR, sale 30,080 shares at $0.67 during a trade that took place back on Jan 17 ’24, which means that Rawcliffe Adrian is holding 44,848 shares at $20,244 based on the most recent closing price.
Stock Fundamentals for ADAP
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.95 for the gross margin
The net margin for Adaptimmune Therapeutics Plc ADR stands at -0.26. The total capital return value is set at -0.19. Equity return is now at value -53.54, with -14.66 for asset returns.
Based on Adaptimmune Therapeutics Plc ADR (ADAP), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -2.18. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -30.04.
Currently, EBITDA for the company is -128.2 million with net debt to EBITDA at 2.42. When we switch over and look at the enterprise to sales, we see a ratio of 0.31. The receivables turnover for the company is 4.53for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.85.
Conclusion
In summary, Adaptimmune Therapeutics Plc ADR (ADAP) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
